Andrew K. Takle

Demonstration of a Genetic Therapeutic Index for Tumors Expressing Oncogenic <i>BRAF</i> by the Kinase Inhibitor SB-590885

Alastair J. King, Denis R. Patrick, Roberta S. Batorsky et al. · Cancer Research · 2006 · 262 citations · Full text

Pathology, Oncogenic Braf Alleles, Tumor Biology +17

The identification of potent and selective imidazole-based inhibitors of B-Raf kinase

Andrew K. Takle, Murray J. B. Brown, Susannah Davies et al. · Bioorganic & Medicinal Chemistry Letters · 2005 · 189 citations · Full text

Medicinal Chemistry, Drug Target, Biochemistry +11

6-Heteroaryl-pyrazolo[3,4-b]pyridines: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3)

Jason Witherington, Vincent Bordas, Alessandra Gaiba et al. · Bioorganic & Medicinal Chemistry Letters · 2003 · 85 citations · Full text

Molecular Pharmacology, Medicinal Chemistry, Biochemistry +10

A New approach to 1,7-dioxaspiro[5.5]undec-4-enes via metallated allenol ethers. Synthesis of Lacrimin A

Andrew K. Takle, Philip Kocieński · Tetrahedron · 1990 · 59 citations

Engineering, Allenol Ethers, New Approach +7

The Role of Disulfide Bond Replacements in Analogues of the Tarantula Toxin ProTx-II and Their Effects on Inhibition of the Voltage-Gated Sodium Ion Channel Na_v1.7

Zoë V. F. Wright, Stephen McCarthy, Rachael Dickman et al. · Journal of the American Chemical Society · 2017 · 53 citations · Full text